Plus: DPP-4 Inhibitor vs Luseogliflozin; more
Tuesday, Aug. 10, 2021 : Issue #1157 |
|
Letter from the Editor
Luseogliflozin is an SGLT-2 inhibitor that has been available since 2014 in Japan, but has never been released in the US. Based on a study that our intern, Torré Anderson, II, Fourth Year Doctor of Pharmacy Candidate, Florida A&M University College of Pharmacy, has for us this week, it may be possible that the company is thinking about making a US entrance.
His feature looks at how changing from a DPP4-I to this SGLT-2 inhibitor can make a big difference in hypertension and related heart problems. Take a look at his article and make a choice as to whether you think the effects are limited to this medication or class wide.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief |
|
| |
|
|
|
TOP STORIES - Diabetes News and Research |
|
| |
|
|
|
| | | | About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control. |
| Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
www.diabetesincontrol.com |
|
|
|
|
| | |
|
|
|
|
